Day: September 4, 2020

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that...

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the company will participate in four upcoming virtual healthcare investor conferences.Citi’s 15th Annual Biopharma Virtual Conference. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a panel presentation titled “Precision Targeted Drugs in Oncology,” on Wednesday, September 9, 2020, at 11:40 a.m. Eastern Time.2020 Wells Fargo Virtual Healthcare Conference. Susan M. Molineaux will participate in an analyst moderated meeting on Thursday, September 10, 2020, at 11:20 a.m. Eastern...

SUNNYVALE, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), a leading provider of cloud customer engagement solutions, today announced it has been invited to participate in the following two investor conferences in September:D.A. Davidson 19th Annual Virtual Software and Internet ConferenceWednesday, September 9th (one-on-one meetings only)Jefferies Virtual Software ConferencePresentation: Tuesday, September 15th at 1:30 pm PTWebcast: https://wsw.com/webcast/jeff135/egan/eGain management will host virtual one-on-one meetings with institutional investors at these conferences. Meetings can be scheduled through the firms hosting the conferences or through MKR Investor Relations, eGain’s investor relations firm, at egan@mkr-group.com.To access a live webcast or replay of the formal presentation at the Jefferies conference,...

NEWPORT BEACH, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”), announced that its power electronics business, Coolisys Technologies Corp. (“Coolisys”), along with partner companies, will be conducting tests of its new electric vehicle (“EV”) charger product line, including innovative charging solutions that are expected to produce a full charge for an EV with a 150-mile range battery in just over 30 minutes. The testing will take place at Coolisys’ new headquarters, located at 1635 South Main Street, Milpitas, CA 95035. Coolisys expects that it will receive initial orders for its EV charger products beginning in the fourth quarter of 2020.The EV charging stations market is projected to reach $27.7 billion by 2027 from an estimated $2.5 billion...

NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that the independent Data Safety Monitoring Board (DSMB) recommended continuation of the Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, following completion of trial’s first interim analysis. The analysis was performed on the first 30% of the total target of randomized patients, with the DSMB reviewing the trial’s primary endpoint, all-cause mortality within 30 days of randomization and all safety data.Mesoblast Chief Medical Officer Dr Fred Grossman said: “We are very pleased with the recommendation by the DSMB. This important trial seeks to confirm whether remestemcel-L improves survival in ventilated COVID-19 patients with moderate to severe...

Press release – No. 47 / 2020Zealand Pharma builds Global Medical Affairs function with world-renowned expertsDr. Danilo Verge and Dr. David Kendall, both of whom have decades of experience in the global diabetes space, have joined Zealand Pharma.Copenhagen, September 4, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has significantly enhanced its capabilities in interactions with the medical community with the appointments of Dr. Danilo Verge and Dr. David Kendall to spearhead its Medical Affairs organization.As Head of Global Medical Affairs at Zealand Pharma, Dr. Danilo Verge will be responsible for all medical activities worldwide related to Zealand Pharma’s metabolic and gastrointestinal franchises...

SCOTTSDALE, Ariz., Sept. 04, 2020 (GLOBE NEWSWIRE) — Electromedical Technologies, Inc. (OTCMKTS:EMED) (“Electromedical Technologies” or the “Company”), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro®, designed to relieve chronic, intractable and acute pain by using frequencies and electro-modulation, is pleased to announce that the Financial Industry Regulatory Authority, Inc. (“FINRA”) has approved the Company’s official symbol change to “EMED” (from “ELCQ”).The stock will begin trading under the “EMED” symbol beginning today, September 4, 2020.“We are pleased to get this step accomplished because it helps to create a more coherent and cohesive public identity for our current and prospective shareholders,” remarked Matthew Wolfson, Electromedical Technologies CEO....

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFULOR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS COMPANY ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR BUY ANY OF THE SECURITIES DESCRIBED HEREIN.Company Announcement no. 11/2020 (04.09.2020)Reference is made to Company Announcement no. 10/2020 regarding the announcement by European Energy A/S (the “Company“) of a procedure in writing (the “Written Procedure“) to seek the approval from the holders (the “Bondholders“) of the Company’s outstanding EUR 200,000,000 Senior Secured Callable...

4 September 2020Disclosure of the total number of voting rights and sharesforming the share capital as at 31 August 2020Information pursuant to article L. 233-8 II of the Code de commerce and articles 223-16 and 223-11 of the AMF General regulation (Règlement général de l’Autorité des marchés financiers)   Attachment20200831 PR monthly voting rights EN

4 septembre 2020Déclaration du nombre total de droits de vote et d’actionscomposant le capital social au 31 août 2020Information prévue par l’article L. 233-8 II du Code de commerce et des articles 223-16 et 223-11 du Règlement général de l’Autorité des marchés financiers :  Pièce jointe20200831 PR monthly voting rights FR